This study explores the use of the Hugo platform to involve study participants in their healthcare and treatments. The Hugo platform may allow researchers to collect better and more accurate real-time health data, from other clinics/hospitals, pharmacies and other electronic devices. The purpose of this research is to see if the use of the Hugo platform is consistent, accurate, cost effective, and time efficient, as it collects and transmits important real-time health information from other clinics/hospitals, pharmacies, and other electronic devices.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05224271.
PRIMARY OBJECTIVES:
I. Evaluate the data aggregation from a patient centered platform over a follow up period for completeness and quality, including externally linked electronic health record (EHR) information, toxicity completion, and the patient reported outcomes (PRO) response rates for study patients, compared with historical pre-coronavirus disease (COVID) cohort of registry patients.
II. To explore biometric information obtained from wearables as it pertains to the toxicity of treatment for patients using a wearable device.
III. To estimate app-based survey completion rates using Hugo-based survey incentive completion (gift cards).
IV. To explore the cost data available on the platform.
OUTLINE:
Patients complete surveys via the Hugo Platform at baseline (before treatment), after treatment, and at 3 and 6 months after treatment. Patients' medical records and Fitbit information are also collected into the Hugo Platform.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationMayo Clinic in Rochester
Principal InvestigatorKimberly S. Corbin
